Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Receptors: ɑ Subtype01:31

Adrenergic Receptors: ɑ Subtype

Adrenoceptors are classified into α and ꞵ classes based on their potencies to catecholamine agonists. α-adrenoceptors show the following order of catecholamine potency:
Adrenaline ≥ Noradrenaline >> Isoprenaline
α-adrenoceptors are further divided into α1 and α2-adrenoceptors.
α1-Adrenoceptors: These receptors are located postsynaptically on the effector organs and cause constriction of smooth muscle mediated by activation of phospholipase C—inositol-1,4,5-trisphosphate...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Drugs Affecting Neurotransmitter Release or Uptake01:21

Drugs Affecting Neurotransmitter Release or Uptake

Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Neurochemical Transmission: Sites of Drug Action01:26

Neurochemical Transmission: Sites of Drug Action

Neurochemical transmission, the conduction of electrical impulses between neurons mediated by neurotransmitters, plays a vital role in various physiological processes. Autonomic drugs exert their effects by modulating neurotransmission within the autonomic nervous system. For instance, drugs such as hemicholinium block the precursor uptake necessary for synthesizing acetylcholine, an essential autonomic neurotransmitter. Following synthesis, neurotransmitters are stored in vesicles. Metyrosine...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genetic Deletion of Adenosine A<sub>2A</sub> Receptors Attenuates Aged-Related Alterations of Glial Cells Morphology and of Inflammasome in the Hippocampus and Prefrontal Cortex of Mice.

Glia·2026
Same author

The antidepressant-like effect of adenosine A<sub>1</sub> receptor over-expression in forebrain neurons does not involve an altered adenosine-mediated control of excitatory synaptic transmission.

Neuropharmacology·2026
Same author

Adenosine A<sub>2A</sub> Receptors Control the Mis-Localization of Aquaporin-4 in Rats Subject to Repeated Restraint Stress.

Journal of neurochemistry·2026
Same author

Astrocytic GPR55 receptors promote glycolysis.

Journal of cannabis research·2026
Same author

Genetic deletion of adenosine A<sub>2A</sub> receptors attenuates memory deterioration and alterations of synaptic plasticity and metabolic controllers in the hippocampus and prefrontal cortex of aged mice.

GeroScience·2026
Same author

Neurophysiological In Vitro Model of Amyloid-β-Induced Deficits of Hippocampal LTP Involving Neuronal Adenosine A<sub>2A</sub> Receptor Dysfunction Through CD73.

Cells·2026

Related Experiment Video

Updated: May 21, 2026

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
06:43

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes

Published on: February 5, 2018

Astrocytic adenosine A2A receptors control the amyloid-β peptide-induced decrease of glutamate uptake.

Marco Matos1, Elisabete Augusto, Nuno J Machado

  • 1CNC -Center for Neuroscience and Cell Biology, University of Coimbra, Coimbra, Portugal.

Journal of Alzheimer'S Disease : JAD
|June 1, 2012
PubMed
Summary

Blocking adenosine A(2A) receptors (A(2A)R) prevents amyloid-β (Aβ) from reducing glutamate uptake in astrocytes. This finding highlights a key role for A(2A)R in Alzheimer's disease (AD) pathology.

More Related Videos

A High-content Assay for Monitoring AMPA Receptor Trafficking
10:34

A High-content Assay for Monitoring AMPA Receptor Trafficking

Published on: January 28, 2019

Visualizing Axonal Growth Cone Collapse and Early Amyloid &#946; Effects in Cultured Mouse Neurons
06:23

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

Related Experiment Videos

Last Updated: May 21, 2026

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes
06:43

A Novel In Vitro Live-imaging Assay of Astrocyte-mediated Phagocytosis Using pH Indicator-conjugated Synaptosomes

Published on: February 5, 2018

A High-content Assay for Monitoring AMPA Receptor Trafficking
10:34

A High-content Assay for Monitoring AMPA Receptor Trafficking

Published on: January 28, 2019

Visualizing Axonal Growth Cone Collapse and Early Amyloid &#946; Effects in Cultured Mouse Neurons
06:23

Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons

Published on: October 30, 2018

Area of Science:

  • Neuroscience
  • Cell Biology
  • Pharmacology

Background:

  • Alzheimer's disease (AD) involves cognitive decline linked to amyloid-β (Aβ) accumulation.
  • Aβ disrupts glutamatergic synapses by impairing astrocytic glutamate uptake.
  • Adenosine A(2A) receptors (A(2A)R) are implicated in AD, with caffeine potentially offering protection via A(2A)R antagonism.

Purpose of the Study:

  • To investigate whether A(2A)R blockade can prevent Aβ-induced reduction in astrocytic glutamate uptake.
  • To elucidate the role of astrocytic A(2A)R in mediating Aβ's effects on glutamate homeostasis.

Main Methods:

  • Primary astrocyte cultures and ex vivo rat gliosomes were used.
  • Cells were treated with Aβ(1-42), A(2A)R agonists (CGS 26180), and antagonists (SCH 58261).
  • Glutamate uptake, GFAP density, and glutamate transporter expression (GLAST, GLT-I) were measured. Genetic A(2A)R knockout mice were utilized.

Main Results:

  • Aβ(1-42) treatment increased GFAP density and decreased D-aspartate uptake in astrocytes, effects mimicked by A(2A)R agonists and blocked by antagonists.
  • Aβ(1-42)-induced reduction in glutamate uptake was abrogated in A(2A)R knockout mice or with pharmacological A(2A)R blockade.
  • Aβ(1-42) enhanced astrocytic A(2A)R expression while decreasing GLAST and GLT-I expression in wild-type but not knockout mice.

Conclusions:

  • Astrocytic A(2A)R play a crucial role in mediating the negative impact of Aβ on glutamate uptake.
  • Aβ impairs astrocytic glutamate transport via A(2A)R-dependent mechanisms.
  • Targeting astrocytic A(2A)R may offer a novel therapeutic strategy for AD by preserving glutamatergic function.